Efficacy and safety of an alpha-blocker with and without anticholinergic agent in the management of lower urinary tract symptoms with detrusor overactivity

UroToday International Journal

Volumn 2, Issue 6, 2009, Pages

  Mohanty, Nayan Kumar ^a   Kumar, Anup ^a   Jain, Manoj ^a   Prakash, Sanjay ^a   Arora, Rajender Prakash ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

Detrusor overactivity; Luts; Medical treatment

Indexed keywords

EID: 72249110857     PISSN: None     EISSN: 19394810     Source Type: Journal    
DOI: 10.3834/uij.1944-5784.2009.12.02     Document Type: Article

References (18)

1. Garraway WM, Collins GN, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet. 1991;338(8774):1076-1077.
2. Speakman MJ. Initial choices and final outcomes in lower urinary tract symptoms. Eur Urol. 2001;40(Suppl 4):21-30.
3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37-49.
4. Rosier PF, de la Rosette JJ, Wijkstra H, Van Kerrebroeck PE, Debruyne FM. Is detrusor instability in elderly males related to the grade of obstruction? Neurourol Urodyn. 1995;14(6):625-633.
5. Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol. 1992;148(5):1549-1564.
6. Abrams P, Feneley R, Torrens M. Urodynamic investigations. In: Abrams, P. Urodynamics. Berlin, Germany: Springer-Verlag; 1983:28-95.
7. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079-1086.
8. Lukacs B, Comet D, Grange JC, Thibault P. Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice. Br J Urol. 1997;80(5):722-730.
9. Chapple CR, Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol. 1994;73(2):117-123.
10. Madersbacher S, Klingler HC, Schatzl G, Stulnig T, Schmidbauer CP, Marberger M. Age related urodynamic changes in patients with benign prostatic hyperplasia. J Urol. 1996;156(5):1662-1667.
11. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651-658.
12. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 pt 1):999-1004.
13. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol. 2005;174:2273-2276.
14. Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006(5); 97:1003-1006.
15. Kaplan SA, Roehrborn CG, Dmochowski R, Rovner ES, Wang JT, Guan Z. Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia. Urology. 2006;68(2):328-332.
16. Lee JY, Kim HW, Lee SJ, Koh JS, Suh HJ, Chancellor MB. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int. 2004;94(6):817-820.
17. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006(19);296:2319-2328.
18. Athanasopoulos A, Gyftopoulos K, Giannitsas K, Fisfis J, Perimenis P, Barbalias G. Combination treatment with an alpha blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized controlled study. J Urol. 2003(6);169:2253-2256.